Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.
Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. Vogels R, et al. J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003. J Virol. 2003. PMID: 12857895 Free PMC article.
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.
Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M. Holterman L, et al. Among authors: vogels r. J Virol. 2004 Dec;78(23):13207-15. doi: 10.1128/JVI.78.23.13207-13215.2004. J Virol. 2004. PMID: 15542673 Free PMC article.
Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH. Lemckert AA, et al. Among authors: vogels r. J Virol. 2005 Aug;79(15):9694-701. doi: 10.1128/JVI.79.15.9694-9701.2005. J Virol. 2005. PMID: 16014931 Free PMC article.
Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.
Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J. Havenga M, et al. Among authors: vogels r. J Gen Virol. 2006 Aug;87(Pt 8):2135-2143. doi: 10.1099/vir.0.81956-0. J Gen Virol. 2006. PMID: 16847108
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.
Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J. Havenga MJ, et al. Among authors: vogels r. Biotechnol Bioeng. 2008 Jun 1;100(2):273-83. doi: 10.1002/bit.21757. Biotechnol Bioeng. 2008. PMID: 18512821 Free PMC article.
249 results